Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

723.51 -8.69 (-1.19%)
Streaming Delayed Price Updated: 11:44 AM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
84 85 Next >
Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments
Beam Therapeutics stock is rising as the company begins to receive significant money from the multiple licensing deals it has in place 
Via MarketBeat
Vivani Medical Surges on its Ozempic-Like Weight-Loss Implant
The Ozempic craze continues to make headlines in the medical sector, and GLP-1 drug stocks such as Vivani Medical continue to surge higher 
Via MarketBeat
Exposures Product Safety
Is Viking Therapeutics Stock a Better Buy Than Eli Lilly and Novo Nordisk After the Latest Weight-Loss Drug News?
A new player in the multibillion-dollar weight-loss drug market could be waiting in the wings. 
Via The Motley Fool
Why Dialysis Stocks DaVita, Fresenius Soared On Novo's Ozempic News
Novo Nordisk tested its diabetes and weight-loss drug in patients with chronic kidney disease. 
Via Investor's Business Daily
Eli Lilly and Co Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
Is It Too Late to Buy Eli Lilly Stock Now?
Eli Lilly stock is having a moment, but the company could easily continue soaring. 
Via The Motley Fool
A Closer Look at 18 Analyst Recommendations For Eli Lilly and Co
Via Benzinga
Prediction: Eli Lilly and Novo Nordisk Stock Could Just be Getting Started. Here's Why
Eli Lilly and Novo Nordisk dominate the diabetes market thanks to blockbuster medications Mounjaro, Ozempic, and Rybelsus. 
Via The Motley Fool
Better Weight Loss Drug Stock: Viking Therapeutics vs. Eli Lilly
One is a reigning champion, and the other is a burgeoning contender. 
Via The Motley Fool
Jim Cramer Says Nvidia, Eli Lilly, Novo Nordisk Are Not Overvalued: 'Will Be Ready To Buy If This Market Sells Off'
Cramer suggested that the upcoming labor report could potentially trigger a buying opportunity, predicting stronger figures than expected by Wall Street. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
It’s Time! 3 Dodgy Pharma Stocks to Sell in February
Explore pharma stocks to sell in February: Eli Lilly, Amgen, BioNTech face overvaluation, volatility, urging investor action. 
Via InvestorPlace
$1000 Invested In This Stock 10 Years Ago Would Be Worth $13,000 Today
Via Benzinga
1 Wall Street Analyst Thinks Eli Lilly Stock Is Going to $1000. Is It a Buy Around $782?
There are two big reasons why Eli Lilly stock is as much as 5x more expensive than Pfizer. 
Via The Motley Fool
Here's How Much You'd Have If You Invested $10,000 in Eli Lilly Stock When Billionaire George Soros First Bought It
The tricky part would have been to not sell the pharmaceutical giant's shares when Soros did. 
Via The Motley Fool
This Is the Biggest Company Not in the "Magnificent Seven" -- but It Deserves to Be
It's in a distinctly different business than the "Magnificent Seven" companies, but it deserves the same attention. 
Via The Motley Fool
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
WHY: NEW YORK, NY - (NewMediaWire) - March 03, 2024 - Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Altimmune,... 
Via NewMediaWire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
WHY: NEW YORK, NY - (NewMediaWire) - March 03, 2024 - Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Altimmune,... 
Via TheNewswire.com
Better Blockbuster-Drug Stock: Novo Nordisk vs. Eli Lilly
This is a close contest, and it'll go on for at least a few more rounds. 
Via The Motley Fool
Better Buy: Eli Lilly vs. Viking Therapeutics
These two biotechs could eventually go head to head in a fast-growing market. 
Via The Motley Fool
3 Magnificent Growth Stocks to Buy in March
These three stocks have two important common denominators: the same industry and tremendous growth prospects. 
Via The Motley Fool
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
WHY: NEW YORK, NY - (NewMediaWire) - March 01, 2024 - Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Altimmune,... 
Via TheNewswire.com
Why Novo Nordisk Stock Topped the Market Today
A favorite of both investors and analysts gets a boost from a bullish move by a pundit. 
Via The Motley Fool
Record-High S&P 500 Propels SPY ETF To $500-Billion Milestone, Nvidia Tops $2 Trillion, Broadcom Surpasses Tesla
U.S. stock market continues bull run, hitting record highs for S&P 500 and Nasdaq 100. SPY ETF surpasses $500 billion AUM, with other companies also reaching milestones. 
Via Benzinga
Topics ETFs Stocks
Exposures US Equities
Eli Lilly's Commercial Moat, Competitor Landscape: BofA Emphasizes Strength in Incretin Space, Undervalued Assets
Eli Lilly: BofA Securities rates it a top pick in Biopharma, with a YTD performance of +29%. Analysts highlight undervalued opportunities in heart disease, sleep apnea, and liver disease. Price target... 
Via Benzinga
Stock Market Rally At Highs After Big Earnings, Inflation Data: Weekly Review
The Nasdaq is on the cusp of setting a record high. 
Via Investor's Business Daily
Topics Economy
Exposures Interest Rates
Eli Lilly Stock And The Road To 1,000: Weight-Loss Drugs Could Generate $81 Billion
Wall Street isn't properly taking into account Lilly's next-generation drugs, an analyst says. 
Via Investor's Business Daily
3 Stocks Showing Constructive Pullbacks with Indexes at New Highs
As the market becomes extended on AI exuberance, leading stocks like MongoDB, Eli Lilly and Adobe are pulling back, potentially offering new buy opportunities. 
Via MarketBeat
Topics Artificial Intelligence ETFs
Exposures Artificial Intelligence
3 Healthcare Stocks That Have Outperformed Nvidia Since 2022
The healthcare sector is no slouch when it comes to top-performing growth stocks. 
Via The Motley Fool
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
84 85 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.